GSK details combo data that could bring Blenrep back to life
GSK`s blood cancer drug meets primary goal in late-stage trial
The United Kingdom’s Medicines and Healthcare Products Regulatory Agency (MHRA) has granted full marketing authorization for selinexor (Nexpovio; Xpovio) in combination with bortezomib (Velcade) and low-dose dexamethasone (SVd) for the treatment of adult patients with multiple myeloma who have received at least 1 prior therapy.1
Akorn's Generic Bortezomib Receives Approval in the U.S.
Waverley's Generic Bortezomib Receives Approval in the U.S.
The Janssen Pharmaceutical Companies of Johnson & Johnson has reported final data from the Phase II GRIFFIN clinical trial of Darzalex (daratumumab) plus lenalidomide (Revlimid), bortezomib (Velcade) and dexamethasone (Darzalex-RVd) in recently diagnosed patients with multiple myeloma.
SMC approve Johnson & Johnson’s systemic light chain amyloidosis therapy
The SMC has accepted the first licensed treatment for adults with newly diagnosed systemic light chain (AL) amyloidosis.